| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW |
Department of Pathology, Baylor College of Medicine and Michael E DeBakey Department of Veterans Affairs Medical Center, Houston, Texas 77030, USA
(Requests for offprints should be addressed to M Ittmann, Research Service, Michael E DeBakey VAMC, 2002 Holcombe Blvd, Houston, Texas 77030, USA; Email: mittmann{at}bcm.tmc.edu)
Prostate cancer is the most common malignancy in men in the USA and the second leading cause of cancer deaths. Fibroblast growth factors (FGFs), including FGF1 (acidic FGF), FGF2 (basic FGF), FGF6 and FGF8 are all expressed at increased levels in prostate cancer as paracrine and/or autocrine growth factors for the prostate cancer cells. In addition, increased mobilization of FGFs from the extracellular matrix in cancer tissues can increase the availability of FGFs to cancer cells. Prostate cancer epithelial cells express all four types of FGF receptors (FGFR-1 to -4) at variable frequencies. Expression of FGFR-1 and FGFR-4 is most closely linked to prostate cancer progression, while the role of FGFR-2 remains controversial. Activation of FGF receptors can activate multiple signal transduction pathways including the phospholipase C
, phosphatidyl inositol 3-kinase, mitogen-activated protein kinase and signal transducers and activators of transcription (STAT) pathways, all of which play a role in prostate cancer progression. Sprouty proteins can negatively regulate FGF signal transduction, potentially limiting the impact of FGF signaling in prostate cancer, but in a significant fraction of prostate cancers there is decreased expression of Sprouty1 mRNA and protein. The effects of increased FGF receptor signaling are wide ranging and involve both the cancer cells and surrounding stroma, including the vasculature. The net result of increased FGF signaling includes enhanced proliferation, resistance to cell death, increased motility and invasiveness, increased angiogenesis, enhanced metastasis, resistance to chemotherapy and radiation and androgen independence, all of which can enhance tumor progression and clinical aggressiveness. For this reason, the FGF signaling system it is an attractive therapeutic target, particularly since therapies targeting FGF receptors and/or FGF signaling can affect both the tumor cells directly and tumor angiogenesis. A number of approaches that could target FGF receptors and/or FGF receptor signaling in prostate cancer are currently being developed.
This article has been cited by other articles:
|
|
 |
|
  I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al. Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target Blood, August 1, 2008; 112(3): 750 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Perera, H. S. Spalding, S. I. Mohammed, and I. G. Camarillo Identification of Proteins Secreted from Leptin Stimulated MCF-7 Breast Cancer Cells: A Dual Proteomic Approach Experimental Biology and Medicine, June 1, 2008; 233(6): 708 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Cotton, M. K. O'Bryan, and B. T. Hinton Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction Endocr. Rev., April 1, 2008; 29(2): 193 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ahmad, S. Attoub, M. N. Singh, F. L. Martin, and O. M. A. El-Agnaf {gamma}-Synuclein and the progression of cancer FASEB J, November 1, 2007; 21(13): 3419 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Sales, S. C. Boddy, A. R. W. Williams, R. A. Anderson, and H. N. Jabbour F-Prostanoid Receptor Regulation of Fibroblast Growth Factor 2 Signaling in Endometrial Adenocarcinoma Cells Endocrinology, August 1, 2007; 148(8): 3635 - 3644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xian, K. L. Schwertfeger, and J. M. Rosen Distinct Roles of Fibroblast Growth Factor Receptor 1 and 2 in Regulating Cell Survival and Epithelial-Mesenchymal Transition Mol. Endocrinol., April 1, 2007; 21(4): 987 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Airoldi, E. Di Carlo, C. Cocco, G. Taverniti, T. D'Antuono, E. Ognio, M. Watanabe, D. Ribatti, and V. Pistoia From the Cover: Endogenous IL-12 triggers an antiangiogenic program in melanoma cells PNAS, March 6, 2007; 104(10): 3996 - 4001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, Y. Lv, Z. Guo, X. Li, Y. Li, J. Zhu, D. Yang, J. Xu, C. Wang, S. Rao, et al. Effects of replacing the unreliable cDNA microarray measurements on the disease classification based on gene expression profiles and functional modules Bioinformatics, December 1, 2006; 22(23): 2883 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hatziapostolou, C. Polytarchou, P. Katsoris, J. Courty, and E. Papadimitriou Heparin Affin Regulatory Peptide/Pleiotrophin Mediates Fibroblast Growth Factor 2 Stimulatory Effects on Human Prostate Cancer Cells J. Biol. Chem., October 27, 2006; 281(43): 32217 - 32226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. K. Loeb, J. L. Harris, and C. S. Craik Granzyme B Proteolyzes Receptors Important to Proliferation and Survival, Tipping the Balance toward Apoptosis J. Biol. Chem., September 22, 2006; 281(38): 28326 - 28335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Fritzsche, M Kenzelmann, M J Hoffmann, M Muller, R Engers, H-J Grone, and W A Schulz Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr. Relat. Cancer, September 1, 2006; 13(3): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhang, J. Kosman, N. Carmean, R. Grady, and J. A. Bassuk FGF-10 and its receptor exhibit bidirectional paracrine targeting to urothelial and smooth muscle cells in the lower urinary tract Am J Physiol Renal Physiol, August 1, 2006; 291(2): F481 - F494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meijer, T. van Agthoven, P. T. Bosma, K. Nooter, and L. C.J. Dorssers Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells Mol. Cancer Res., June 1, 2006; 4(6): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. P. Milling Smith, S. Battersby, K. J. Sales, H. O. D. Critchley, and H. N. Jabbour Prostacyclin Receptor Up-Regulates the Expression of Angiogenic Genes in Human Endometrium via Cross Talk with Epidermal Growth Factor Receptor and the Extracellular Signaling Receptor Kinase 1/2 Pathway Endocrinology, April 1, 2006; 147(4): 1697 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhong, G. Saribekyan, C.-P. Liao, M. B. Cohen, and P. Roy-Burman Cooperation between FGF8b Overexpression and PTEN Deficiency in Prostate Tumorigenesis Cancer Res., February 15, 2006; 66(4): 2188 - 2194. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
